Selecting patients for magnetic resonance imaging cognitive versus ultrasound fusion biopsy of the prostate: A within-patient comparison

Mitch Hayes1 | Solange Bassale2 | Nicholas H. Chakiryan1 | Luc Boileau1 | Jacob Grassauer1 | Matthew Wagner3 | Bryan Foster4 | Fergus Coakley4 | Sudhir Ishaarwal1 | Christopher L. Amling1 | Jen-Jane Liu1

1Department of Urology, Oregon Health & Science University, Portland, Oregon, USA
2Knight Cancer Institute, Biostatistics Shared Resources, Oregon Health and Science University, Portland, Oregon, USA
3Department of Urology, Kaiser Permanente, Portland, Oregon, USA
4Department of Radiology, Oregon Health and Science University, Portland, Oregon, USA

Correspondence
Jen-Jane Liu, MD, Department of Urology, Oregon Health and Science University, 3303 SW Bond Ave, CH10U, Portland, OR 97239, USA.
Email: jenj@ohsu.edu

Funding information
Oregon Health and Science University Lloyd

Abstract

Objectives: To compare overall agreement between magnetic resonance imaging (MRI)–ultrasound (US) fusion biopsy (FB) and MRI cognitive fusion biopsy (CB) of the prostate and determine which factors affect agreement for prostate cancer (PCa) who underwent both modalities in a prospective within-patient protocol.

Patients and Methods: From August 2017 to January 2021, patients with at least one Prostate Imaging Reporting & Data System (PI-RADS) 3 or higher lesion on multiparametric MRI underwent transrectal FB and CB in a prospective within-patient protocol. CB was performed for each region of interest (ROI), followed by FB, followed by standard 12 core biopsy. Patients who were not on active surveillance were analysed. The primary endpoint was agreement for any PCa detection. McNemar’s test and kappa statistic were used to analyse agreement. Chi-square test, Fisher’s exact test and Wilcoxon rank sum test were used to analyse disagreement across clinical and MRI spatial variables. A multivariable generalized mixed-effect model was used to compare the interaction between select variables and fusion modality. Statistics were performed using SAS and R.

Results: Ninety patients and 98 lesions were included in the analysis. There was moderate agreement between FB and CB (κ = 0.715). McNemar’s test was insignificant (p = 0.285). Anterior location was the only variable associated with a significant variation in agreement, which was 70% for anterior lesions versus 89.7% for non-anterior lesions (p = 0.035). Discordance did not vary significantly across other variables. In a mixed-effect model, the interaction between anterior location and use of FB was insignificant (p = 0.411).

Conclusion: In a within-patient protocol of patients not on active surveillance, FB and CB performed similarly for PCa detection and with moderate agreement. Anterior location was associated with significantly higher disagreement, whereas other patient and lesion characteristics were not. Additional studies are needed to determine optimal biopsy technique for sampling anterior ROI.

DOI: 10.1002/bco2.172

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
1 | INTRODUCTION

Multiparametric prostate magnetic resonance imaging (MRI) (mpMRI) increases detection of high-grade prostate cancer (PCa) and decreases detection of low-grade cancers compared with standard template prostate biopsy.\(^1\)–\(^4\) To accurately target regions of interest (ROIs), fusion biopsy (FB) requires precise contouring by radiologists, and software-guided co-registration of the ROI and prostate contours onto transrectal ultrasound (TRUS) images. FB also requires capital investment to acquire the specialized technology necessary to overlay the images. Cognitive fusion biopsy (CB) allows targeting of MRI-visible ROIs without FB technology. CB relies on the urologist’s ability to accurately target the ROI without direct illustrated guidance from a co-registered target. Prior studies comparing CB and FB have had mixed results. Some have shown similar detection rates for high-grade PCa between CB and FB, whereas others have shown an advantage with FB.\(^5\)–\(^10\) Multiple systematic reviews and a meta-analysis have not shown a difference in high-grade cancer detection between CB and FB.\(^11\)–\(^12\)

Thus, for diagnostic purposes, it is not clear what advantage software registration confers over simply knowing where an MRI suspicious ROI is located within the prostate. In patients with an elevated prostate-specific antigen (PSA) and positive MRI, urologists who do not have access to FB technology must decide between proceeding with CB or referral to a centre with FB equipment. We are interested in determining if there are patient selection criteria that can optimally identify which technique to use. The primary objective of this study was to compare PCa detection rate between CB and FB and examine the effect of spatial parameters on performance of the two modalities side by side in patients who underwent both CB and FB.

2 | PATIENTS AND METHODS

2.1 | Study population

This study was conducted after approval of the local Institutional Review Board. Eligible patients with Prostate Imaging Reporting & Data System 3 (PI-RADS 3) or greater ROIs were enrolled. Patients with a prior MRI-ultrasound (US) FB or in-bore MRI-guided biopsy were excluded. Patients with PSA > 100 ng/ml or radiographic evidence of metastatic cancer, and those taking any type of androgen suppression were excluded. Patients who underwent any prior attempt at definitive local PCa therapy, radiation or otherwise, were also excluded. Patients were excluded from the analysis if they had already been diagnosed with PCa (i.e., undergoing confirmatory biopsy and/or on active surveillance). Agreement and multivariable analyses were performed on a per ROI basis.

2.2 | Diagnostic imaging

The majority of mpMRIs were performed at 3-Tesla with an endo-rectal coil using the technical standards set forth by PI-RADS v2. All mpMRI, including the few not performed at our institution, were interpreted by two diagnostic radiologists (BF, FC) with extensive mpMRI experience using PI-RADS v2 criteria. Prostate and ROI contouring was performed using Dynacad software (Invivo, Philips, Best, Netherlands).

2.3 | Biopsy procedure details

All biopsies were performed by three fellowship-trained urologic oncologists (JJL, SI, CLA) with extensive experience in fusion and standard TRUS biopsy. One of the surgeons performed FB prior to this study in training, while the other two surgeons had been performing FB for 2 years prior to initiation of the study. Informed consent was obtained, and biopsies were conducted per protocol, not as standard of care. The protocol is as follows. First, a TRUS was performed (BK Medical, Peabody, MA), and two cores from the targeted ROI on MRI were obtained using the CB technique, sampling either a TRUS-visible hypoechoic ROI corresponding to the region identified by MRI or the general area specified by MRI if no hypoechoic ROI could be identified. Second, the MRI target ROI and prostate contour were co-registered with the TRUS image using the UroNav FB device (Invivo, Philips, Best, Netherlands), and two cores were obtained from the ROI. If multiple ROIs were present, CB of all ROIs was performed first. FB followed in the standard fashion. Finally, a 12-core standard sextant systematic biopsy was obtained.

2.4 | Outcomes

Overall, cancer detection was the primary outcome and defined as any Gleason 3 + 3 or higher found in one or more cores for the ROI on biopsy final pathology. High-grade cancer detection was a secondary outcome and defined as any Gleason 3 + 4 or higher found in one or more cores for the ROI on biopsy final pathology.

2.5 | Statistical analysis

McNemar’s test was used to analyse overall agreement of any PCa detection between CB and SB.

Agreement was then assessed across specific pre-biopsy clinical and MRI spatial parameters. These included clinical variables that are known or suspected to affect cancer detection rate, namely, age,
Patient-level demographics

|                        | N = 90 patients |
|------------------------|-----------------|
| Age, years             | 68 (64, 74)     |
| PSA, ng/ml             | 7 (6, 11)       |
| PSA density, ng/mlb    | 0.14 (0.09, 0.23)|
| Positive family history of PC | 21 (23%)        |
| Abnormal DRE           | 33 (38%)        |
| Prior negative biopsy  | 48 (53%)        |
| Prostate volume on MRI, ml | 52 (35, 78)  |
| Highest PI-RADS score  |                |
| 3                      | 12 (13%)        |
| 4                      | 39 (43%)        |
| 5                      | 39 (43%)        |
| Combined Biopsy Gleason Gradec |            |
| No cancer              | 32 (36%)        |
| 3 + 3                  | 11 (12%)        |
| 3 + 4                  | 14 (16%)        |
| 4 + 3                  | 12 (13%)        |
| 4 + 4 or higher        | 21 (23%)        |

Abbreviations: CB, MRI cognitive fusion biopsy; DRE, digital rectal exam; FB, MRI-US fusion biopsy; MRI, magnetic resonance imaging; PC, prostate cancer; PI-RADS, Prostate Imaging Reporting & Data System; PSA, prostate-specific antigen; US, ultrasound.

Table 1A

| TABLE 1A | Patient-level demographics |
|----------|-----------------------------|
|          |                             |
|          | N = 90 patients              |
|          |                             |
|          | Age, years 68 (64, 74)       |
|          | PSA, ng/ml 7 (6, 11)         |
|          | PSA density, ng/ml 0.14 (0.09, 0.23) |
|          | Positive family history of PC 21 (23%) |
|          | Abnormal DRE 33 (38%)        |
|          | Prior negative biopsy 48 (53%) |
|          | Prostate volume on MRI, ml 52 (35, 78) |
|          | Highest PI-RADS score        |
|          | 3 12 (13%)                  |
|          | 4 39 (43%)                  |
|          | 5 39 (43%)                  |
|          | Combined Biopsy Gleason Grade |
|          | No cancer 32 (36%)          |
|          | 3 + 3 11 (12%)              |
|          | 3 + 4 14 (16%)              |
|          | 4 + 3 12 (13%)              |
|          | 4 + 4 or higher 21 (23%)    |

3 | RESULTS

3.1 | Patient and tumour characteristics

Ninety patients and 98 ROIs were included in the study. The median age was 68, and median PSA was 7 ng/ml. Sixty-four percent of patients were diagnosed with any cancer, and 52% of patients were diagnosed with Gleason grade group 2 or higher. High-grade cancer detection rate for both targeted biopsy techniques amongst all ROIs was 48%. High-grade cancer detection rate amongst all ROIs was 40% for FB, and 43% for CB. Tables 1A and 1B summarize patient-level and ROI-level characteristics. Fifty-three percent of all patients had a prior negative biopsy.

3.2 | Concordance

Overall, concordance between FB and CB was 85.7% for all ROIs. FB detected cancer where CB did not in nine ROIs (9%). CB detected cancer where FB did not in five ROIs (5%) (Table 2A). McNemar’s test was insignificant (p = 0.285). Cohen’s kappa coefficient for agreement for any cancer was 0.71 (‘moderate agreement’).13 Concordance for high-grade cancer was 86.7%. FB detected high-grade cancer where CB did not in five ROIs (5%). CB detected high-grade cancer where FB did not in eight ROIs (8%) (Table 2A). McNemar’s test was insignificant (p = 0.579). Cohen’s kappa coefficient for agreement for any cancer was 0.73 (‘moderate agreement’).15

3.3 | Agreement across pre-biopsy variables

Agreement was stratified by age, PSA, family history of PCa, DRE, ROI location of base, apex, or anterior, prostate volume, ROI maximum dimension, transverse dimension, anteroposterior dimension, craniocaudal dimension, and ROI volume (Table 2B). There was no significant difference in agreement across selected variables except anterior location of the ROI. Amongst anterior ROIs, agreement between CB and FB was 70% versus 89.7% for non-anterior ROIs (p = 0.035).

3.4 | Multivariable analysis with interaction variables

As anterior location was the only significant variable from the agreement analysis, this was selected and included in the generalized mixed-effect model as part of an interaction term between anterior location and fusion modality. Neither the modality main effect nor the interaction terms were significant, suggesting neither modality was superior for the detection of PCa in our cohort. As expected, anterior location was statistically significant for PCa detection (p = 0.015). The odds ratio of any cancer detection in anterior lesions compared with non-anterior lesions was 3.06 (95% confidence interval [CI] 1.3, 7.4) (Table 3).

4 | DISCUSSION

This study found that in a within-patient protocol, there was moderate agreement for the detection of any PCa between CB and FB all patients
with no prior cancer history. The detection rate for high-grade PCa was 40% for FB, and 43% for CB, which is consistent with prior studies and meta-analysis that have shown no difference in cancer detection rate between the two modalities.

However, there is heterogeneity amongst prior prospective studies comparing CB with FB; thus, it remains unclear the optimal fusion modality for targeted biopsy, particularly for those that do not have ready access to the technology for FB. The advantage of our within-patient design is that confounding variables are perfectly balanced, which allows a direct comparison of the technical performance of the two modalities. Our findings that FB and CB perform similarly for the detection of PCa (including high-grade PCa) reinforce prior studies. There are profound implications for practice patterns (referrals, streamlining care) and overall system cost-effectiveness if CB were to be adopted as equivalent to FB.

It is a reasonable expectation that there could be certain factors that could favour FB; however, this study did not identify a specific selection criterion that benefits from FB over CB. Stratified by patient and MRI lesion characteristics, agreement was moderate between the two modalities amongst patients with no prior history of cancer except for anterior ROI location, where agreement was nearly 20% lower. Although anterior location was associated with a higher incidence of PCa detection on multivariable analysis, neither FB nor CB detected cancer at a higher rate for anterior lesions. Thus, it is not possible to conclude that either is superior.

One possibility as to why disagreement is higher amongst anterior lesions specifically is that there is more deformation of tissue to reach these targets due to increased distance from needle entry point. The advent of targeted MRI visible lesions has likely not surmounted the challenge of sampling the anterior zone of the prostate with transrectal biopsy approaches. This is reinforced by the higher rate of PCa detection in anterior lesions on multivariable analysis, as patients may have had anterior cancers that were missed with prior negative standard template biopsy as is known to occur commonly.\textsuperscript{14,15} For this reason, urologists must continue to give special attention to patients with MRI visible anterior tumours to avoid diagnostic sampling error. Further studies are needed to determine if these patients may be better served by alternate biopsy techniques, such as MRI-guided in-bore or transperineal biopsy, which are becoming increasingly utilized at tertiary referral centers.\textsuperscript{16–19}

As we have seen in this study, FB does not appear to be superior to CB in this setting, but the high rate of disagreement suggests that negative results of any transrectal FB should be interpreted with caution.

### Table 1B ROI-level characteristics

|                  | N = 98 ROIs<sup>a</sup> |
|------------------|--------------------------|
| Transverse dim.  | 1.25 (0.90, 1.70)        |
| Anteroposterior dim. | 1.00 (0.70, 1.20)       |
| Craniocaudal dim. | 1.20 (0.78, 1.70)        |
| Maximum dim.     | 1.45 (1.00, 1.92)        |
| Lesion volume    | 0.70 (0.30, 1.50)        |
| PI-RADS score    |                          |
| 3                | 14 (14%)                 |
| 4                | 44 (45%)                 |
| 5                | 40 (41%)                 |
| Anterior location|                          |

Abbreviations: CB, MRI cognitive fusion biopsy; FB, MRI-US fusion biopsy; PI-RADS, Prostate Imaging Reporting & Data System; ROI, region of interest; US, ultrasound.

<sup>a</sup>Median (IQR); n (%).

### Table 2A Overall agreement between cognitive and MRI-US fusion

| Agreement | Any cancer | High-grade cancer |
|-----------|------------|-------------------|
| Both FB + CB positive | 41 (42%) | 34 (35%) |
| FB negative + CB positive | 5 (5%) | 8 (8%) |
| FB positive + CB negative | 9 (9%) | 5 (5%) |
| Both FB + CB negative | 43 (44%) | 51 (52%) |
| Cohens kappa | 0.71 | 0.73 |
| p value<sup>b</sup> | 0.285 | 0.579 |

Abbreviations: CB, MRI cognitive fusion biopsy; FB, MRI-US fusion biopsy; MRI, magnetic resonance imaging; US, ultrasound.

<sup>b</sup>McNemars test.
4.1 Limitations

Our study sampled two cores for each modality for a total of four cores. Multiple groups have shown that four biopsy cores of MRI visible regions will detect more high-grade PCa compared with one or two cores. Thus, the overall cancer detection rate for individual targeting strategies in our study could be lower than if four cores were taken. However, because our interest was in directly comparing the technical performance of the fusion modalities, each modality should be at an equal disadvantage. It is possible that the discordance

---

**TABLE 2B** Agreement between cognitive and MRI-US fusion across variables

|                        | Agreement (N = 84 ROIs) | Disagreement (N = 14 ROIs) | p value<sup>b</sup> |
|------------------------|-------------------------|-----------------------------|--------------------|
| Age, years             | 68.9 (8.2)              | 69.6 (7.5)                  | 0.5185             |
| PSA, ng/ml             | 9.7 (6.5)               | 7.2 (3.4)                   | 0.1612             |
| PSA density, ng/ml<sup>+</sup> | 0.2 (0.2)           | 0.1 (0.1)                   | 0.1737             |
| Positive family history of PC |                     |                             |                    |
| No/NA                  | 63 (84%)                | 12 (16%)                    | 0.5134             |
| Yes                    | 20 (93.8%)              | 2 (6.3%)                    |                    |
| DRE                    |                         |                             |                    |
| Normal                 | 49 (83.1%)              | 10 (16.9%)                  | 0.4674             |
| Abnormal               | 31 (88.6%)              | 4 (11.4%)                   |                    |
| Prior negative biopsy  |                         |                             |                    |
| No                     | 42 (89.4%)              | 5 (10.6%)                   | 0.3219             |
| Yes                    | 42 (82.4%)              | 9 (17.6%)                   |                    |
| Prostate volume on MRI, ml | 58.5 (33.6)          | 56.5 (22)                   | 0.6809             |
| PI-RADS score          |                         |                             |                    |
| 3                      | 13 (92.9%)              | 1 (7.1%)                    | 0.6849             |
| 4 and 5                | 71 (84.5%)              | 13 (15.5%)                  |                    |
| Transverse dimension, cm | 1.4 (0.8)             | 1.2 (0.5)                   | 0.2704             |
| Anteroposterior dimension, cm | 1 (0.6)             | 1 (0.4)                     | 0.7786             |
| Craniocaudal dimension, cm | 1.3 (0.7)            | 1.3 (0.6)                   | 0.8271             |
| Maximum dimension, cm  | 1.6 (0.8)              | 1.4 (0.6)                   | 0.4924             |
| ROI volume, cc         | 1.7 (3.4)              | 1.1 (1.1)                   | 0.864              |
| Base location          |                         |                             |                    |
| No                     | 62 (88.6%)              | 8 (11.4%)                   | 0.2146             |
| Yes                    | 22 (78.6%)              | 6 (21.4%)                   |                    |
| Anterior location      |                         |                             |                    |
| No                     | 70 (89.7%)              | 8 (10.3%)                   | 0.0352*            |
| Yes                    | 14 (70%)                | 6 (30%)                     |                    |

**TABLE 3** Multivariable analysis of interaction term with anterior lesion location for PC detection

| Variable                           | OR (95% CI) | p value |
|------------------------------------|-------------|---------|
| MRI-US fusion (vs. cognitive)      | 0.7 (0.4, 1.3) | 0.332   |
| Anterior (vs. non-anterior)        | 3.1 (1.3, 7.4) | 0.015   |
| MRI-US fusion (vs. cognitive) in anterior lesions | 0.6 (0.2, 1.9) | 0.411   |
| MRI-US fusion (vs. cognitive) in non-anterior lesions | 0.9 (0.7, 1.2) | 0.478   |

Abbreviations: CB, MRI cognitive fusion biopsy; DRE, digital rectal exam; FB, MRI-US fusion biopsy; MRI, magnetic resonance imaging; PC, prostate cancer; PI-RADS, Prostate Imaging Reporting & Data System; PSA, prostate-specific antigen; ROI, region of interest; US, ultrasound.

<sup>a</sup>Median (IQR); n (%).

<sup>b</sup>Systematic biopsy and both fusion modalities.

*Statistically significant (p < 0.05).
amongst anterior ROIs might decrease with increased sampling. More research is needed in order to compare the core for core performance of transperineal fusion approaches and other fusion approaches such as transperineal fusion or MRI in core-guided biopsy. Other limitations include the relatively large size of the lesions included in this study, which may have precluded detection of a difference between the two techniques as larger lesions could be more successfully sampled via cognitive FB. Larger lesion size was likely due to the exclusion of active surveillance patients with smaller lesions, and availability of MRI in core biopsy in our institution, which may have been preferentially used in the case of very small lesions.

Additionally, the performance of FB may have been impacted by the known learning curve for FB. The success of FB is determined by accurate contouring and co-registration of the prostate and ROI outlines onto the TRUS images. Small errors in either of these steps, or deformation of the prostate during mpMRI or FB, could result in errors in co-registration of the target ROI. However, we do not believe that FB or CB had a performance advantage over the other as operators started performing both modalities around the same time period. Thus, this factor is less likely to have an impact when comparing modalities.

This study was performed at a tertiary academic referral centre. Prostate MRIs were interpreted, and target ROIs were marked by specialized radiologists experienced in analysing prostate mpMRI (BF and FC). All three of the urologists in the study were fellowship trained urologic oncologists experienced in TRUS-guided biopsy (SI, CLA, JYL). Applicability of these findings may be limited for general urology practices or with mpMRI obtained with different techniques and read by general radiologists, where there is known interobserver variability in interpretation. However, we believe that with the increased diffusion of prostate MRI into practice and most urologists having reasonable existing experience with TRUS, that use of CB techniques should still be feasible and beneficial to those without access to SB.

5 | CONCLUSION

Cognitive fusion has a similar cancer detection rate of all and high-grade PCa as MRI-US fusion via the transrectal approach in a within-patient comparison, but with moderate agreement. Agreement did not significantly vary across most clinical and MRI variables except amongst anterior ROI locations. Anterior tumours continue to pose a challenge in PCA diagnosis using a transrectal approach. Utilization of cognitive fusion with standard template TRUS biopsy is a viable strategy for urologists without access to MRI-US fusion technology. Given the limitations of transrectal biopsy for anterior ROIs, alternative biopsy strategies should be considered when the suspicion for PCa persists following negative targeted transrectal biopsy of anterior ROIs.

ACKNOWLEDGEMENT

This research was funded by the Oregon Health and Science University Lloyd research grant (JYL).

AUTHOR CONTRIBUTION

Study concept and design: Mitch Hayes and Jen-Jane Liu. Analysis and interpretation of data: Mitch Hayes, Luc Boileau, Jacob Grasseur, Solange Bassale, Nicholas Chakiryan. Drafting of the manuscript: Mitch Hayes and Jen-Jane Liu. Critical revision of the manuscript for important intellectual content: Mitch Hayes, Matthew Wagner, Bryan Foster, Fergus Coakley, Sudhir Isharwal, Christopher Amling, Jen-Jane Liu. Obtained funding: Jen-Jane Liu.

ORCID

Mitch Hayes https://orcid.org/0000-0003-3240-9946
Nicholas H. Chakiryan https://orcid.org/0000-0001-9263-8957

REFERENCES

1. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22. https://doi.org/10.1016/S0140-6736(16)32401-1
2. Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate magnetic resonance imaging with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and Meta-analysis. Eur Urol. 2020;77(1):78–94. https://doi.org/10.1016/j.euro.2019.06.023
3. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR-ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7. https://doi.org/10.1001/jama.2014.17942
4. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaara MH, et al. MRI-targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med. 2018;378(19):1767–77. https://doi.org/10.1056/NEJMoa1801993
5. Lee DJ, Recabal P, Sjoberg DD, Thong A, Lee JK, Eastham JA, et al. Comparative effectiveness of targeted prostate biopsy using magnetic resonance imaging ultrasound fusion software and visual targeting: a prospective study. J Urol. 2016;196(3):697–702. https://doi.org/10.1016/j.juro.2016.03.149
6. Wegelin O, Exerkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The future trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate Cancer in patients with prior negative biopsies. Eur Urol. 2019;75(4):582–90. https://doi.org/10.1016/j.euro.2018.11.040
7. Monda SM, Vetter JM, Andriole GL, Fowler KJ, Shetty AS, Weese JR, et al. Cognitive versus software fusion for MRI-targeted biopsy: experience before and after implementation of fusion. Urology. 2018;119:115–20. https://doi.org/10.1016/j.urology.2018.06.011
8. Stabile A, Dell’Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, et al. Not all multiparametric magnetic resonance imaging-targeted biopsies are equal: the impact of the type of approach and operator expertise on the detection of clinically significant prostate Cancer. Eur Urol Oncol. 2018;1(2):120–8. https://doi.org/10.1016/j.euo.2018.02.002
9. Puech P, Rouvière O, Renard-Penna R, Villers A, Devos P, Colombel M, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy—prospective multicenter study. Radiology. 2013;268(2):461–9. https://doi.org/10.1148/radiol.13121501
10. Oberlin DT, Casalino DD, Miller FH, Matulewicz RS, Perry KT, Nadler RB, et al. Diagnostic value of guided biopsies: fusion and cognitive-registration magnetic resonance imaging versus conventional ultrasound biopsy of the prostate. Urology. 2016;92:75–9. https://doi.org/10.1016/j.urology.2016.02.041

11. Watts KL, Frechette L, Muller B, Linksy D, Kovac E, Sankin A, et al. Systematic review and meta-analysis comparing cognitive vs. image-guided prostate biopsy for the detection of prostate cancer. Urol Oncol. 2020;38(9):734.e19. https://doi.org/10.1016/j.urolonc.2020.03.020

12. Wegelin O, van Melick HHE, Hooft L, Bosch J, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a Preferred Technique? Eur Urol. 2017;71(4):517–31. https://doi.org/10.1016/j.eururo.2016.07.041

13. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82. https://doi.org/10.11613/BM.2012.031

14. Leyh-Bannurah SR, Kachanov M, Beyersdorf F, Preisser F, Tilki D, Fisch M, et al. Anterior localization of prostate cancer suspicious lesions in 1,161 patients undergoing magnetic resonance imaging-ultrasound fusion guided targeted biopsies. J Urol. 2018;200(5):1035–40. https://doi.org/10.1016/j.juro.2018.06.026

15. Radtke JP, Boxler S, Kuru TH, Wolf MB, Alt CD, Popeneiciu IV, et al. Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer Prostatic Dis. 2015;18(3):288–96. https://doi.org/10.1038/pcan.2015.29

16. Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, et al. Magnetic resonance imaging-guided in-bore and magnetic resonance imaging-transrectal ultrasound fusion targeted prostate biopsies: an adjusted comparison of clinically significant prostate cancer detection rate. Eur Urol Oncol. 2019;2(4):397–404. https://doi.org/10.1016/j.euro.2018.08.022

17. Prince M, Foster BR, Kaempf A, Liu JJ, Amling CL, Isharwal S, et al. In-bore versus fusion MRI-targeted biopsy of PI-RADS category 4 and 5 lesions: a retrospective comparative analysis using propensity score weighting. AJR Am J Roentgenol. 2021;217(5):1123–30. https://doi.org/10.2214/AJR.20.25207

18. Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, et al. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World J Urol. 2017;35(12):1849–55. https://doi.org/10.1007/s00345-017-2085-6

19. Tu X, Liu Z, Chang T, Qiu S, Xu H, Bao Y, et al. Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer. 2019;17(5):e860–70. https://doi.org/10.1016/j.clgc.2019.05.006

20. Calio BP, Sidana A, Sugano D, Gaur S, Maruf M, Jain AL, et al. Risk of upgrading from prostate biopsy to radical prostatectomy pathology—does saturation biopsy of index lesion during multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy help? J Urol. 2018;199(4):976–82.

21. Kenigsberg AP, Renson A, Rosenkrantz AB, Huang R, Wysock JS, Taneja SS, et al. Optimizing the number of cores targeted during prostate magnetic resonance imaging fusion target biopsy. Eur Urol Oncol. 2018;1(5):418–25. https://doi.org/10.1016/j.euo.2018.09.006

22. Halstuch D, Daniel J, Lifshitz D, Sela S, Ber Y, Margel D. Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer Prostatic Dis. 2019;22(4):546–51. https://doi.org/10.1038/s41391-019-0137-2

23. Ruprecht O, Weisser P, Bodelle B, Ackermann H, Vogl TJ. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81(3):456–60. https://doi.org/10.1016/j.ejrad.2010.12.076

How to cite this article: Hayes M, Bassale S, Chakiryam NH, Boileau L, Grassauer J, Wagner M, et al. Selecting patients for magnetic resonance imaging cognitive versus ultrasound fusion biopsy of the prostate: A within-patient comparison. BJUI Compass. 2022;3(6):443–449. https://doi.org/10.1002/bco2.172